Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cell Cycle Regulation Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDPF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDPF1 Recombinant Protein (Full-Length/Truncated) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CDPF1 Products |
| Gene Delivery | CDPF1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression assays. |
View CDPF1 Products |
| Benchmark Ab | Anti-CDPF1 Recombinant Antibody High-affinity positive control for WB, IHC, and IP validation. |
View CDPF1 Products |
| Validator | CDPF1 siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View CDPF1 Products |
| Related Target A | CDK4 Key G1/S transition kinase; synergizes with CDPF1-mediated cell cycle progression. |
View CDK4 Products |
| Related Target B | CCND1 Cyclin D1; downstream effector and co-regulator in CDPF1-driven oncogenesis. |
View CCND1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent conformational stability | HEK293 expressed CDPF1 with native post-translational modifications, sequence verified for calcium-binding domain integrity. |
| Intracellular target validation | High-titer Lentivirus particles and validated siRNA sets for robust knock-in and knock-down functional assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant positive controls included. |
| False Positives | Validated siRNA included for target-specificity and off-target background screening. |
Live CDPF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CDPF1 (Calcium-binding and coiled-coil domain-containing protein 1) is emerging as a novel frontier in cell cycle-targeted oncology. CDPF1 plays a critical role in promoting the G1/S transition, and its overexpression is strongly correlated with poor prognosis in non-small cell lung cancer (NSCLC), breast cancer, and colorectal malignancies.
As traditional cell cycle inhibitors (such as CDK4/6 inhibitors) face challenges with acquired clinical resistance, the next wave of R&D is shifting toward upstream regulators and scaffold proteins like CDPF1. Modulating CDPF1 offers a strategic pathway to overcome drug resistance, particularly in combination therapies targeting the cyclin-CDK axis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic & Biotech Consortia | NSCLC, Breast Cancer | High-purity recombinant protein for binding affinity assays and thermal shift assays. |
| PROTAC / Degraders | Preclinical Startups | Refractory Solid Tumors | Lentivirus-driven stable cell lines for protein degradation kinetics monitoring. |
| siRNA Therapeutics | RNAi Developers | Advanced Malignancies | Validated siRNA controls and transfection-ready target sequences to benchmark knockdown efficiency. |